3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
3
Rectal Neoplasms
2
Carcinoma
2
Prostatic Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Multiple Myeloma
1
Colonic Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
padeliporfin
4
Nivolumab
4
Gemcitabine
4
Cyclophosphamide
4
130-nm albumin-bound paclitaxel
4
napabucasin
3
Pemetrexed
3
Fluorouracil
3
Albumin-Bound Paclitaxel
3
ficlatuzumab
2
Trastuzumab
2
Trabectedin
2
Paclitaxel
2
Leucovorin
2
Irinotecan
2
Bevacizumab
2
sotorasib
1
selinexor
1
ribociclib
1
relatlimab
1
pralsetinib
1
pembrolizumab
1
pamiparib
1
osimertinib
1
nintedanib
1
ipatasertib
1
guadecitabine
1
glutathione pegylated liposomal doxorubicin
1
exemestane
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms by Site
×
L-BLP25
×
Clear all
NCT01507103
2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
124 enrolled
9 charts